James Kelly, MD
Ophthalmology · New York, NYNPI 1659361848
Payments from drug & device makers
Across 416 payments — averaging $40.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Alcon$8K
- Carl Zeiss Meditec, Inc.$1K
- Sun Pharmaceutical Industries Inc.$1K
- Harrow Eye, LLC$906
- Johnson & Johnson Surgical Vision, Inc.$866
- Bausch & Lomb Americas Inc.$709
- plus $3K from 22 others
What the payments were for
- Speaking & faculty fees$1,0506%
- Travel & lodging$120%
- Food & beverage$15,69394%
- Gifts$190%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Alcon | 134 | $8,121 |
| Carl Zeiss Meditec, Inc. | 15 | $1,414 |
| Sun Pharmaceutical Industries Inc. | 77 | $1,276 |
| Harrow Eye, LLC | 21 | $906 |
| Johnson & Johnson Surgical Vision, Inc. | 22 | $866 |
| Bausch & Lomb Americas Inc. | 22 | $709 |
| NEW World Medical,inc. | 5 | $568 |
| AbbVie(2 entities) | 24 | $511 |
| Novartis | 23 | $414 |
| Tarsus Pharmaceuticals, Inc. | 9 | $315 |
| Kala Pharmaceuticals, Inc. | 13 | $280 |
| Rxsight Inc | 6 | $244 |
| Dompe US, Inc. | 7 | $190 |
| Oyster Point Pharma, Inc. | 7 | $187 |
| Glaukos Corporation | 1 | $114 |
| Amgen(2 entities) | 5 | $113 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 4 | $86 |
| Mallinckrodt Hospital Products Inc. | 3 | $81 |
| Ocular Therapeutix, Inc. | 3 | $58 |
| Carl Zeiss Meditec USA, Inc. | 1 | $53 |
| Staar Surgical Company | 1 | $52 |
| Eyevance Pharmaceuticals LLC | 2 | $50 |
| Shire North American Group Inc | 2 | $50 |
| Rayner Intraocular Lenses Limited | 2 | $48 |
| Sight Sciences, Inc. | 2 | $36 |
| Carl Zeiss Meditec AG | 1 | $19 |
| Genentech USA, Inc. | 1 | $15 |
| Rapid Pathogen Screening, Inc. | 3 | $0 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- AcrySof IQ PanOptix UV IOL$1,050
- VisuMax$1,026
- Clareon$661
- ARGOS$659
- enVista MX60 IOL$600
- AcrySof IQ PanOptix$522
- LenSx$413
- Clareon PanOptix Pro$392
- ACTIVEFOCUS$387
- ILUX$257
- AcrySof$250
- Wavelight$236
- RXSIGHT CONTACT LENS$163
- RXSIGHT INJECTOR CARTRIDGE$163
- RXSIGHT INJECTOR HANDPIECE$163
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$163
- LIGHT ADJUSTABLE LENS (LAL)$163
- Tecnis Simplicity$149
- PanOptix$148
- Unity$145
How this compares
$16,775 in reported general payments places this provider in the 85th percentile of 1,587 ophthalmology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 306 | $277,845 |
| XiidraLifitegrast | 116 | $140,812 |
| MieboPerfluorohexyloctane/Pf | 91 | $66,683 |
| Restasis MultidoseCyclosporine | 80 | $50,815 |
| CequaCyclosporine | 77 | $45,559 |
| Cyclosporine | 44 | $19,286 |
| CombiganBrimonidine Tartrate/Timolol | 42 | $9,664 |
| Tobradex StTobramycin/Dexamethasone | 37 | $8,368 |
| Prednisolone Acetate | 217 | $6,495 |
| LumiganBimatoprost | 14 | $5,490 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 22 | $4,308 |
| LotemaxLoteprednol Etabonate | 11 | $3,656 |
| Brimonidine Tartrate | 40 | $3,511 |
| Latanoprost | 321 | $2,570 |
| Ketorolac Tromethamine | 119 | $1,916 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Restasis Multidose, Combigan, Lumigan | $511 | $343,813442 claims |
| Bausch & Lomb Americas Inc.Xiidra, Miebo | $709 | $207,495207 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,276 | $45,55977 claims |
| Eyevance Pharmaceuticals LLCTobradex St | $50 | $8,36837 claims |
| AlconSimbrinza | $8,121 | $4,30822 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax | $86 | $3,65611 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 1,587 ophthalmology providers in New York.
Other ophthalmology in New York
- Douglas JabsNew York$24.3M
- Nathan RadcliffeNew York$2.4M
- Richard SpaideNew York$1.7M
- Jason SlakterNew York$1.2M
- David ChuNew York$1.2M
- Sharon KehNew York$941K
- Joshua YoungNew York$814K
- Joseph PanarelliNew York$704K
- Joshua KimNew York$677K
- Eric RosenbergNew York$526K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.